Requests for Proposals
RFP-1.0 Vector Production and Purification – revised April 17, 2018
RFP-2.0 Thawing, Sterile Filtering, and Vial Filling – revised April 9, 2021
RFP-3.0 Characterization – revised February 15, 2019
Vector Production and Purification
Status: Purified material was shipped from NRC to ATCC in the last quarter of 2023 – Official Letter, April 9, 2021
NRC-Canada Production Specifics – March 2021
NRC-Canada Preliminary Planning – February 2019
Use and Availability
Sterile filtration and vialing scheduled for Fall 2024. Material will then be made available for purchase at ATCC.
Project Documentation
Meeting Minutes – Norfolk, Virginia: March 5, 2019
Meeting Minutes – Norfolk, Virginia: March 6, 2018
Meeting Minutes – Washington, DC: March 7, 2017
Meeting Minutes – Washington, DC: March 8, 2016
Meeting Minutes – Washington, DC: March 10, 2015
Presentations
An Overview of the LVV-RM Initiative – Washington, DC: March 7, 2017
References and Related Articles
Scalable Lentiviral Vector Production Using Stable HEK293SF Producer Cell Lines
Lentivirus Working Group Participants
Participant List – August 24, 2020
Contributions Received
Keith Carson, LVV-RM Executive Committee Coordinator:
Contributor Acknowledgements – March 2021
Services, products, and consumables donated – as of April 2021
Contributors
We would like to express our sincere appreciation for the consumable products and testing services these fine organizations have donated to the Lentiviral Vector Reference Material Project (LVV-RM).
This reference material will be used by organizations that are developing lentiviruses for use in gene and cellular therapies to help qualify, or validate, their internal reference material and assays.
Data developed and compared to the LVV-RM will provide tremendous value to the organization developing a product, as well as FDA CBER, which can use the LVV-RM to compare product submissions.
